Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer Therapy
Management of breast cancer depends on improving understanding of adjuvant therapy
November 10th, 2005
The future management of breast cancer depends on improving our biological understanding of adjuvant endocrine therapy, a researcher in England asserts. According to a recent study published in the European Journal of Cancer, "Tamoxifen has been the standard of care for adjuvant endocrine therapy of early breast cancer. In postmenopausal women, data now suggest that alternative agents (aromatase inhibitors [AIs]) may have improved long-term risk:benefit profiles and thus have the potential to improve outcome." "The 'Arimidex', Tamoxifen, alone or in combination (ATAC) trial has shown that anastrozole provides improved disease-free survival...
Source: Women's Health Weekly (2005-11-10)
|
